Clovis Oncology(CLVS) up 34% towards market close
Clovis Oncology Inc.(CLVS) currently trades at $7.39 and has grown 43% in the past 24 hours. On the 4Q2019 earnings report, Rubraca delivered approximately 30% year-over-year sales growth. Additionally, Clovis reduced its operating cash burn in 2H2019 by 46%.
Based on this information, investorsQ rates this stock a 6 out of 10. We give it this rating because Clovis has seen consistent growth and holds a good position in the coronavirus world. With this said, it is true that the coronavirus bear market indeed knocked down Clovis shares far beyond their true worth. The high forecast for Clovis Oncology Inc. is $32 and the low is $3. Notably, the company’s market cap is $531.04 million with a 52 week high of $25.88 and a 52 week low of $2.93.